Integration of Automated Insulin Delivery System with One-Year CGM by Sequel Med Tech and Senseonics
In a significant move, Sequel Med Tech and Senseonics Holdings have entered a commercial development agreement to integrate Sequel's Twiist™ automated insulin delivery (AID) system with Senseonics' Eversense 365 continuous glucose monitoring (CGM) system. This collaboration, scheduled for a Q4 2025 launch, aims to transform diabetes care by combining Senseonics' one-year CGM sensor with Sequel Med Tech’s smart insulin pump technology.
The integrated system offers several key features designed to improve diabetes management. Eversense 365, with its implantable sensor lasting up to 365 days, reduces the need for frequent replacements. The Twiist insulin pump employs sound wave technology for precise real-time insulin delivery and customizable settings, such as personalized blood sugar targets as low as 87 mg/dL.
Users can also select from different absorption rates (fast, standard, slow) which help the algorithm tailor insulin delivery more accurately after meals. Predictive blood sugar forecasting continuously updates a six-hour forecast every five minutes, automatically adjusting basal insulin to maintain target glucose levels and prevent highs and lows. Flexible control options allow insulin dosing to be managed via the pump, a connected iPhone app, or Apple Watch.
Pharmacy access is another advantage, as Twiist plans to be available through retail pharmacies, facilitating easier access and reduced commitment. This integration is expected to enhance diabetes management by combining a long-term implantable CGM with an advanced AID system for greater convenience, tighter glucose control, and personalization.
The collaboration also presents opportunities for Senseonics, such as unlocking new revenue streams by entering the growing AID market. It also expands the patient base and reduces reliance on third-party payers, supported by Medicare reimbursement improvements and direct-to-consumer campaigns.
People living with type 1 diabetes who choose to use Twiist will have the flexibility to select from two compatible CGM partners, the Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor. In September 2024, Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system for people with diabetes.
This integrated product marks a significant advancement in automated insulin delivery combined with a one-year CGM system. This collaboration also illustrates Senseonics’ strategic momentum towards future innovations in diabetes technology. Sequel remains committed to advancing diabetes technology and expanding partnerships to give people with diabetes more choice and flexibility in how they manage their diabetes.
The agreement between Sequel and Senseonics is a testament to the ongoing efforts in the diabetes technology sector to provide people with diabetes with more tools for better management, potentially leading to improved glucose control, increased convenience, and greater flexibility.
- This collaboration between Sequel Med Tech and Senseonics Holdings is set to revolutionize diabetes care by integrating medical plastics technology in the form of Sequel's Twiist™ automated insulin delivery system with Senseonics' Eversense 365 continuous glucose monitoring system.
- The integrated system, scheduled for a Q4 2025 release, will leverage advanced technology to offer personalized features for diabetes management, such as adjustable absorption rates, predictive blood sugar forecasting, and various control options for insulin dosing.
- The combination of a long-term implantable CGM with Sequel Med Tech’s smart insulin pump technology aims to provide increased convenience, tighter glucose control, and personalization for those managing chronic diseases like type-2 diabetes or medical-conditions related to diabetes.
- The strategic partnership is expected to benefit both companies, with Senseonics gaining access to new revenue streams in the automated insulin delivery market and Sequel expanding its patient base while promoting health-and-wellness through nutrition and diabetes management innovations.
